Estimates Revisions Relmada Therapeutics, Inc.
Stocks
RLMD
US75955J4022
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
23:00:00 08/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 3.170 USD | -2.46% |
|
-15.92% | -34.37% |
| 09-21 | Relmada Therapeutics, Inc.(NasdaqCM:RLMD) added to S&P Global BMI Index | CI |
| 09-11 | Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- RLMD Stock
- Consensus Relmada Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
